Clinical Trial Detail

NCT ID NCT02417701
Title TORC1/2 Inhibitor MLN0128 in Treating Patients With Stage IV or Recurrent Lung Cancer
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements yes
Sponsors National Cancer Institute (NCI)
Indications

lung squamous cell carcinoma

Therapies

Sapanisertib

Age Groups: adult

Additional content available in CKB BOOST